RNK08954

DRUG2 trials

Sponsors

Ranok Therapeutics (Hangzhou) Co., Ltd.

Conditions

Food EffectKRAS G12D MutationsMass BalancePancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects

Not yet recruitingNCT07334262

Ranok Therapeutics (Hangzhou) Co., Ltd.Food Effect, Mass Balance

Start: 2025-12-31End: 2026-12-01Target: 24Updated: 2026-01-14

Phase 2

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

RecruitingNCT07303465

Ranok Therapeutics (Hangzhou) Co., Ltd.KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)

Start: 2025-10-14End: 2026-11-30Target: 60Updated: 2025-12-24